World Tuberculosis Day 2024 – We can End TB!
World Tuberculosis Day serves as a poignant reminder to raise awareness about tuberculosis (TB). Despite the efforts and promising developments in the fight against this disease, TB remains an endemic that leads to 1.3 million deaths each year. 24 March 2024 Innovations in medical science and public health strategies have provided powerful tools in the […]
MTBVAC, the first vaccine against Tuberculosis derived from a human source, begins clinical trials in adults in India.
MTBVAC, the Spanish tuberculosis vaccine, the first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, reaches a new milestone by starting clinical trials in India, the most populated country in the world and the one with the highest number of cases of this infectious disease. Please read the press release for more information: Spanish […]
Bill & Melinda Gates Medical Research Institute Initiates Phase 3 Clinical Trial of Tuberculosis Vaccine Candidate
The Bill & Melinda Gates Medical Research Institute (Gates MRI) today (19 March 2024) announced that a Phase 3 clinical trial to assess the efficacy of the M72/AS01E tuberculosis (TB) vaccine candidate is now underway, with first doses given in South Africa, where TB takes a heavy toll. If shown to be well-tolerated and effective, […]
TBVI announces the appointment of its new Executive Director
March 2024 – The TBVI Governance Board is pleased to announce the appointment of a new Executive Director of the organisation. Tuberculosis (TB) stands as one of the most persistent and formidable infectious diseases, exerting a substantial burden on global health. Despite progress in healthcare, TB remains a leading cause of morbidity and mortality, particularly in […]
Les Diablerets 2024 (presentations are now available)
On January 30-31, 2024, the TBVI Symposium was held in Les Diablerets, Switzerland. This year, the symposium brought together over 120 tuberculosis (TB) vaccine researchers, developers, funders and policymakers that are all part of TBVI’s network of over 60 research institutes, universities, industrial partners and funding agencies from 20 countries. To encourage synergy and knowledge […]
May the New Year bring you renewed hope, good health and happiness
The TBVI team wishes you and your loved ones a joyful holiday season. May the New Year bring you renewed hope, good health and happiness. We want to express our heartfelt gratitude to all our partners. Together, we are committed to eliminating the burden of TB worldwide by our shared creativity, endurance and the […]
Announcement awardees of the TBVI Young Scientist Award 2023-2024
To encourage talented young scientists and recognise outstanding contributions to TB vaccine research and development, in October TBVI published the TBVI Young Scientist Awards 2024. It is our pleasure to announce the three winners of the 2023-2024 award: Paul Ogongo Paul grew up in Kenya where he got his bachelor’s and master’s degrees. In 2019 […]
Save the date – 7th Global Forum October 2024
The Working Group on New TB Vaccines (WGNV), IAVI, and the TuBerculosis Vaccine Initiative (TBVI), in partnership with the Ministry of Health of Brazil and the Brazilian TB Research Network (REDE-TB), are pleased to announce that the 7th Global Forum on TB Vaccines will be held in Rio de Janeiro, Brazil from 8 – 10 […]
Global TB Report 2023
The WHO published the Global TB Report 2023. This report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease. In 2022 TB-related deaths, including those among people with HIV, was 1.3 million. You can read the report here: Global TB Report 2023
Call for applications to assess efficacy of Mycobacterium tuberculosis vaccine candidates in a mouse model
Diversification of the vaccine development pipeline has been identified as a priority area in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium has been able to secure funds for a 4-year project that aims, amongst other things, to fill the early phases of the development pipeline while ensuring a diverse portfolio (https://www.tbvi.eu/projects/tbvac-horizon/). One of the […]